Heidi S Camp

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes
    H S Camp
    Department of Cell Biology and Endocrinology, Pfizer Global Research and Development, University of Michigan Medical School, Ann Arbor, Michigan 48105, USA
    Endocrinology 142:3207-13. 2001
  2. ncbi request reprint Adipogenesis and fat-cell function in obesity and diabetes
    Heidi S Camp
    Department of Molecular Sciences and Technology, Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Trends Mol Med 8:442-7. 2002
  3. ncbi request reprint Thiazolidinediones in diabetes: current status and future outlook
    Heidi S Camp
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Curr Opin Investig Drugs 4:406-11. 2003
  4. pmc PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis
    Delin Ren
    Department of Molecular Science and Technology, Pfizer Global and Research Development, Ann Arbor, Michigan 48105, USA
    Genes Dev 16:27-32. 2002
  5. ncbi request reprint Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors
    W Yang
    Department of Molecular Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    J Biol Chem 276:38341-4. 2001
  6. pmc Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes
    Todd Leff
    Department of Pathology and the Center for Integrative Metabolic and Endocrine Research, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Exp Diabesity Res 5:99-109. 2004
  7. ncbi request reprint Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
    Barbara Cool
    Department of Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    Cell Metab 3:403-16. 2006
  8. ncbi request reprint Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors
    Yu Gui Gu
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 49:3770-3. 2006
  9. ncbi request reprint The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modifications
    Xiangdong Xu
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:1803-7. 2007
  10. ncbi request reprint Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents
    Richard F Clark
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:1961-5. 2007

Collaborators

  • Yu Gui Gu
  • J F Waring
  • Bradley A Zinker
  • Rongqi Wang
  • Xiaolin Zhang
  • Xiaojun Wang
  • Bruce A Beutel
  • Xiangdong Xu
  • Hing L Sham
  • Richard F Clark
  • Barbara Cool
  • Todd Leff
  • Delin Ren
  • W Yang
  • Moshe Weitzberg
  • Tianyuan Zhang
  • Robert F Keyes
  • Qun Li
  • Ernst U Frevert
  • Paul Jung
  • Andrew Adler
  • Gerard Gagne
  • Matthew Perham
  • Robert Dickinson
  • Philip Kym
  • Lemma Kifle
  • William Chiou
  • Gang Zhao
  • Kennan Marsh
  • Ning Cao
  • Rajesh Iyengar
  • Ernst Frevert
  • Suresh T Mathews
  • Trevor N Collingwood
  • Edward J Rebar
  • Alan P Wolffe
  • X q Shen
  • Y H Hong
  • T Leff
  • C Frankowski

Detail Information

Publications11

  1. ncbi request reprint A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes
    H S Camp
    Department of Cell Biology and Endocrinology, Pfizer Global Research and Development, University of Michigan Medical School, Ann Arbor, Michigan 48105, USA
    Endocrinology 142:3207-13. 2001
    ..These results suggest that in terminally differentiated adipocytes, the PPARgamma activity is minimal and may not be required for the maintenance of PPARgamma target gene expression...
  2. ncbi request reprint Adipogenesis and fat-cell function in obesity and diabetes
    Heidi S Camp
    Department of Molecular Sciences and Technology, Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Trends Mol Med 8:442-7. 2002
    ..Here, we review new advances in our understanding of adipogenesis and fat-cell function, primarily from the perspective of the transcription factor peroxisome proliferator-activated receptor gamma...
  3. ncbi request reprint Thiazolidinediones in diabetes: current status and future outlook
    Heidi S Camp
    Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Curr Opin Investig Drugs 4:406-11. 2003
    ..Understanding the molecular basis for these differences will help in the development of next generation thiazolidinediones that are more efficacious and safer for the treatment of type 2 diabetes...
  4. pmc PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis
    Delin Ren
    Department of Molecular Science and Technology, Pfizer Global and Research Development, Ann Arbor, Michigan 48105, USA
    Genes Dev 16:27-32. 2002
    ..Overexpression of exogenous gamma2 in the ZFP54-expressing cells completely restored adipogenesis, whereas overexpression of gamma1 had no effect. This finding clearly identifies a unique role for the PPARgamma2 isoform...
  5. ncbi request reprint Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors
    W Yang
    Department of Molecular Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    J Biol Chem 276:38341-4. 2001
    ..Our results suggest a direct link between cellular energy metabolism and gene expression...
  6. pmc Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes
    Todd Leff
    Department of Pathology and the Center for Integrative Metabolic and Endocrine Research, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Exp Diabesity Res 5:99-109. 2004
    ..Here the authors review the current status of PPARgamma research, with an emphasis on its role in the causes and treatment of type 2 diabetes...
  7. ncbi request reprint Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
    Barbara Cool
    Department of Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    Cell Metab 3:403-16. 2006
    ..These results demonstrate that small molecule-mediated activation of AMPK in vivo is feasible and represents a promising approach for the treatment of type 2 diabetes and the metabolic syndrome...
  8. ncbi request reprint Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acetyl-CoA carboxylase 2 inhibitors
    Yu Gui Gu
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 49:3770-3. 2006
    ..S)-Enantiomer 9p exhibited high ACC2 activity and lowered muscle malonyl-CoA dose-dependently in acute rodent studies, whereas (R)-enantiomer 9o was weak and had no effect on the malonyl-CoA level...
  9. ncbi request reprint The synthesis and structure-activity relationship studies of selective acetyl-CoA carboxylase inhibitors containing 4-(thiazol-5-yl)but-3-yn-2-amino motif: polar region modifications
    Xiangdong Xu
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:1803-7. 2007
    ..Replacement of the hydroxyurea group with isoxazoles improves ACC2 selectivity while maintaining potency. Variations at the propargylic site of 11a reduce ACC2 potency...
  10. ncbi request reprint Phenoxy thiazole derivatives as potent and selective acetyl-CoA carboxylase 2 inhibitors: Modulation of isozyme selectivity by incorporation of phenyl ring substituents
    Richard F Clark
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:1961-5. 2007
    ..Modifications that generally impart high levels of ACC2 selectivity (>3000-fold) while maintaining excellent ACC2 potency (IC50s approximately 9-20 nM) were identified...
  11. ncbi request reprint N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors--improvement of cardiovascular and neurological liabilities via structural modifications
    Yu Gui Gu
    Global Pharmaceutical Research and Development, Abbott Laboratories, 200 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 50:1078-82. 2007
    ..Replacement of the alkyne with alternative linker groups led to a new series of ACC inhibitors with drastically improved cardiovascular and neurological profiles...